Answer to the review from Halstead and Russell “Protective and immunological behavior of chimeric yellow fever dengue vaccine” (DOI 10.1016/j.vaccine.2016.02.004)

Vaccine

Volumn 34, Issue 36, 2016, Pages 4273-4274

  Hadinegoro, Sri Rezki S ^a   Arredondo García, Jose Luis ^b   Guy, Bruno ^c   Bouckenooghe, Alain ^d   Noriega, Fernando ^c   Jackson, Nicholas ^c  

^a CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^b INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^c SANOFI PASTEUR   (France)

^d Sanofi Pasteur Clinical Development Department   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; YELLOW FEVER VACCINE;

DENGUE; DENGUE VIRUS; DRUG EFFICACY; HUMAN; INFECTION PREVENTION; INFECTION RATE; LETTER; PRIORITY JOURNAL; SECONDARY INFECTION; VACCINATION; YELLOW FEVER; IMMUNOLOGY; YELLOW FEVER VIRUS;

DENGUE; DENGUE VACCINES; DENGUE VIRUS; HUMANS; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 84981299152     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.06.015     Document Type: Letter

References (6)

1. [1] Hadinegoro, S.R., Arredondo-García, J.L., Capeding, M.R., Deseda, C., Chotpitayasunondh, T., Dietze, R., et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373 (2015), 1195–1206.
2. [2] Coudeville L, Baurin N, Vergu E. Fitting a transmission model to data from two large phase III vaccine efficacy studies. Vaccine, in press. http://dx.doi.org/10.1016/j.vaccine.2015.11.023.
3. [3] Guy, B., Jackson, N., Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol 14 (2016), 45–54.
4. [4] Hadinegoro SR, Wartel Tram A, Frago C, Zambrano B, Langevin E, Gailhardou S, et al. Long-term safety of the CYD-TDV dengue vaccine in Asia-Pacific dengue endemic countries. In: 5th Pan American dengue research meeting; 2016. Abstract #R86.
5. [5] Guy B, Moser J, Byers AM, Kachurin A, Pagnon A, de Montfort A, et al. Immunological investigations to understand the outcome of the phase III efficacy studies of the Sanofi Pasteur candidate dengue vaccine. In: ASTMH 64th annual meeting; 2015. Abstract #553.
6. [6] Byers, A.M., Broder, R., Haupfear, K., Timiryasova, T., Hu, B.T., Boaz, M., et al. Influence of FcγRIIa-expressing cells on the assessment of neutralizing and enhancing serum antibodies elicited by a live attenuated tetravalent dengue vaccine. Open Forum Infect Dis, 2(4), 2015 ofv172.